iCanWork: A Randomized Controlled Trial
Launched by MCGILL UNIVERSITY · Sep 19, 2022
Trial Information
Current as of July 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The iCanWork trial is a study designed to help people who have survived cancer get back to work and improve their quality of life. Researchers want to see if a special program called the iCanWork intervention can support cancer survivors in returning to their jobs, which can also help them feel better overall. This study will look at various factors, such as how ready participants are to go back to work, how long it takes them to return, and how this affects their health and use of healthcare services.
To be eligible for this trial, participants must be between 18 and 65 years old at the time of their cancer diagnosis, have been working (full-time or part-time) when diagnosed, and currently be on sick leave due to their cancer. They should not have started returning to work since stopping because of their illness, must live in Canada, and be able to read and understand English or French. It’s important to note that individuals whose doctors believe returning to work would be unsafe, like those with advanced cancer, will not be included in this study. If you or someone you know fits these criteria, this trial may offer valuable support during the journey to returning to work after cancer.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • diagnosed with cancer (all types) treated with curative intent and of working age (between 18 and 65 at the time of diagnosis)
- • gainfully employed at the time of diagnosis (full or part-time, including students)
- • still on sick leave, including long-term disability leave, but for less than 2 years
- • has not started to return to work, since stopping due to cancer
- • can read and understand English or French
- • reside in Canada.
- Exclusion Criteria:
- • - If the cancer survivor's physicians consider returning to work unwise, such as due to a metastatic cancer diagnosis
About Mcgill University
McGill University, a prestigious research institution located in Montreal, Canada, is committed to advancing medical science through innovative clinical trials. Renowned for its rigorous academic standards and collaborative approach, McGill fosters a dynamic environment that integrates cutting-edge research with clinical practice. With a focus on improving patient outcomes, the university's clinical trials span a wide range of therapeutic areas, leveraging the expertise of its diverse faculty and state-of-the-art facilities. McGill University is dedicated to ethical research practices and the dissemination of knowledge, ensuring that findings contribute meaningfully to the global healthcare landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Montréal, Quebec, Canada
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials